Gaiting Liu

Dr. Gaiting Liu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GWGuohua Wang
Guohua Wang
YZYige Zhao
Yige Zhao
GLGaiting Liu
Gaiting Liu
YDYuhang Du
Yuhang Du
SLShuchang Liu
Shuchang Liu
BZBaosheng Zhao
Baosheng Zhao
Diabetes mellitus (DM) is a progressive metabolic disorder in which mitochondrial dysfunction is increasingly recognized as a central contributor to metabolic deterioration and diabetic complications. However, whether dysregulated mitochondrial dynamics represents a primary pathogenic driver, an adaptive response, or a consequence of metabolic stress remains incompletely understood. This review summarizes current advances in the molecular mechanisms governing mitochondrial fission, fusion, and mitophagy, with particular emphasis on their coordinated roles in mitochondrial quality control rather than isolated morphological changes. We discuss how disrupted mitochondrial dynamics contributes to pancreatic β-cell dysfunction, insulin resistance, diabetic nephropathy (DN), diabetic cardiomyopathy (DCM), diabetic retinopathy (DR), and diabetic osteoporosis (DOP) through context-dependent regulation of oxidative stress, bioenergetics, inflammation, and endoplasmic reticulum–mitochondria crosstalk. Furthermore, we critically evaluate emerging therapeutic strategies, including metformin, sodium–glucose cotransporter 2 inhibitors, mitochondrial fission inhibitors, and mitochondria-targeted antioxidants, highlighting both their therapeutic potential and current translational challenges. We propose that restoring the physiological equilibrium among mitochondrial fission, fusion, and mitophagy, rather than unidirectionally inhibiting a single pathway, represents a more promising strategy for preventing and treating diabetes and its complications.

5 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
YZYige Zhao
Yige Zhao
YDYuhang Du
Yuhang Du
JXJiamei Xie
Jiamei Xie
SLShuchang Liu
Shuchang Liu
BZBaosheng Zhao
Baosheng Zhao
Background/Objectives: Impaired glucose tolerance (IGT) is a prediabetic condition affecting over 600 million adults worldwide. Mulberry leaf (Morus alba L.) has shown antidiabetic potential, but whether adipose AMPKα1 is required for its effects remains unclear. This study aimed to determine whether mulberry leaf water extract (MLE) ameliorates IGT through adipose AMPKα1-mediated gut microbiota modulation and thermogenesis. Methods: Adipose-specific AMPKα1 knockout (AKO) mice and floxed controls (Flox) were fed a high-fat diet for 12 weeks to establish IGT, then treated with MLE or short-chain fatty acids (SCFAs) for 10 weeks. Metabolic parameters, gut microbiota (16S rRNA sequencing), fecal SCFAs, and AMPKα1/SIRT1/PGC-1α pathway expression were assessed. Results: In Flox mice, MLE and SCFAs significantly improved glucose tolerance, reduced serum lipids and hepatic steatosis, and enhanced brown adipose tissue activation and white adipose browning. These effects were accompanied by gut microbiota remodeling, elevated fecal acetate/propionate/butyrate, and upregulation of the AMPKα1/SIRT1/PGC-1α pathway. All these metabolic and microbiota benefits were abrogated in AKO mice, in which MLE failed to improve any parameter, with only minimal and functionally insignificant thermogenic gene/protein upregulation. Conclusions: Adipose AMPKα1 is essential for MLE to improve IGT via gut microbiota/SCFAs and thermogenesis. These findings identify adipose AMPKα1 as a molecular target for dietary intervention in prediabetes.